Phathom Presents 31 Vonoprazan Abstracts, Phase 3 Analysis Earns Poster Distinction
PHAT•Phathom Pharmaceuticals showcased 31 vonoprazan abstracts at Digestive Disease Week 2026, including 28 independent studies on GERD, H. pylori eradication, long-term safety and post-ESD care plus three company-sponsored posters. Its Phase 3 pHalcon-NERD-301 analysis on heartburn and regurgitation earned Poster of Distinction recognition.
1. Conference Overview
At Digestive Disease Week 2026 in Chicago, Phathom Pharmaceuticals showcased 31 vonoprazan-related abstracts, reflecting extensive clinical interest in VOQUEZNA across gastroenterology. The presentations included three company-sponsored studies alongside multiple investigator-initiated analyses.
2. Independent Research
Academic and clinical scientists across the US, Europe, Asia and South America presented 28 independent abstracts on GERD, H. pylori eradication, long-term safety and post-endoscopic submucosal dissection care. Key topics included meta-analyses comparing healing outcomes in severe erosive esophagitis, network meta-analyses of 77 trials for H. pylori regimens and real-world safety comparisons versus PPIs.
3. Company-Sponsored Findings
Phathom presented three sponsored posters, notably a Phase 3 pHalcon-NERD-301 analysis on heartburn and regurgitation which earned Poster of Distinction, a recognition for notable scientific merit. Additional company analyses evaluated vonoprazan in PPI-refractory GERD patients and subgroup outcomes in elderly and comorbid cohorts.
4. Commercial Implications
The breadth and depth of vonoprazan research underscore growing scientific engagement and may support VOQUEZNA’s positioning in treatment guidelines, enhancing Phathom’s commercialization strategy and potential market uptake.
